1Frisc Study Group. Low - molecular - weight hearin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet, 1996, (347):561.
2Husted SE, Wallentin L, Lagerqvist B, et al. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J,2002 23(15):1213.
4US Pharmacopeia National Formulary. XIII, USA[S]. 1995,736-738.
5中国药典(二部)[M].北京:化学工业出版社和人民卫生出版社,1995:307-308.
6[5]US Pharmacopeia National Formulary.XIII,USA,1995,736～738.
7[7]中国药典(二部)[M].北京:化工出版社和人民卫生出版社,1995,307～308.
8[11]Rostoker G,Durand-Zaleski I,Petit-Phar M,et al.Prevention of thrombotic complications of the nephrotic syndrome the low-molecular-weight heparin enoxaparin[J].Nephron,1995,69(1);20～28.
9[12]Pross M,Lippert H,Nestler G,et al.Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study[J].Int J Colorectal Dis,2004,19(1):143～146.
10[15]Koch A,Ziegler S,Breitschwerdt H,et al.Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis:meta-analysis based on original patient data[J].Thrombosis Research,2001,102(4):295～309.
